EFFICIENCY AND SAFETY OF TREATMENT IN PATIENTS WITH LOW BACK PAIN

Download full text PDF
Issue: 
3
Year: 
2016

M. Magomedova (1); Professor P. Kamchatnov (2), MD 1 -Central Town Hospital, Izberbash, Republic of Dagestan 2 -N.I. Pirogov Russian National Research Medical University, Moscow

Low back pain (LBP) is one of the most common musculoskeletal pain syndromes in the population. Many patients need repeated treatment cycles, during which the risk of undesirable side effects increases. The results of using Nolodatak (flupirtine) that has analgesic, myorelaxant, and neuroprotective effects in LBP are analyzed.

Keywords: 
rheumatology
low back pain
musculoskeletal pain syndromes
flupirtine
nolodatak
treatment
hepatotoxicity



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Hoy D., March L., Brooks P. et al. The global burden of low back pain: estimates from the Global Burden of Disease 2010 study // Ann. Rheum. Dis. – 2014; 73: 968–74.
  2. Sivasubramaniam V., Patel H., Ozdemir B. et al. Trends in hospital admissions and surgical procedures for degenerative lumbar spine disease in England: a 15-year time series study // BMJ Open. – 2015; 5: e009011. doi:10.1136/bmjopen-2015- 009011
  3. Vos T., Flaxman A., Naghavi M. et al. Years lived with disability (YLDs) for 3. 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010 // Lancet. – 2012; 380: 2163–96.
  4. Esin R.G., Lotfullina N.Z., Esin O.R. Tservikalgija, dorzalgija, ljumbal gija. Differentsial'naja diagnostika, differentsirovannaja terapija / Kazan': IITs UD Prezidenta RT, 2015; 420 s.
  5. Ueberall1 A., Eberhardt A., Mueller-Schwefe H. Quality of life under oxycodone/naloxone, oxycodone, or morphine treatment for chronic low back pain in routine clinical practice // Int. J. Gen. Med. – 2016; 9: 39–51.
  6. Brown D., Passmore G. Neural KCNQ (Kv7) channels // Br. J. Pharmacol. – 2009; 156 (8): 1185–95.
  7. Szelenyi I. Flupirtine, a rediscovered drug, revisited // Inflamm. Res. – 2013; 7. 62 (3): 251–8.
  8. Fleckenstein J., Sittl R., Averbeck B. et al. Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo – therapeutic potential for peripheral neuropathies: results of a randomised controlled trial // J. Transl. Med. – 2013; 11: 34–9.
  9. Kornhuber J., Bleich S., Wiltfang J. et al. Flupirtine shows functional NMDA receptor antagonism by enhancing Mg2+ block via activation of voltage independent potassium channels // J. Neural. Transm. – 1999; 106 (9–10): 857–67.
  10. Harish S., Bhuvana K., Bengalorkar M. et al. Flupirtine: Clinical pharmacology // J. Anaesthesiol. Clin. Pharmacol. – 2012; 28 (2): 172–7.
  11. Klawe C., Maschke M. Flupirtine: pharmacology and clinical applications of a nonopioid analgesic and potentially neuroprotective compound // Expert Opin. Pharmacother. – 2009; 10 (9): 1495–500.
  12. Mueller-Schwefe G. Flupirtine in acute and chronic pain associated with muscle tenseness. Results of a postmarket surveillance study // Fortschr. Med. Orig. – 2003; 121 (1): 11–8.
  13. Worz R., Stroehmann I. Ruckemschmerzen: Leitlinien der medicamentosen therapie // Munch. Med. Wschr. – 2000; 142: 27–33.
  14. Uberall M., Mueller-Schwefe G., Terhaag B. Efficacy and safety of flupirtine modified release for the management of moderate to severe chronic low back pain: results of SUPREME, a prospective randomized, double-blind, placebo- and active-controlled parallel-group phase IV study // Curr. Med. Res. Opin. – 2012; 28 (10): 1617–34.
  15. Kamchatnov P.R. Batysheva T.T., Ganzhula P.A. i dr. Primenenie katado lona u bol'nyh so spondilogennoj dorsopatiej // Zhurn. nevrol. i psihiat. im. S.S. Korsakova. – 2006; 106 (11): 46–9.
  16. Douros A., Bronder E., Andersohn F. et al. Drug-induced liver injury: results from the hospital-based Berlin Case-Control Surveillance Study // Br. J. Clin. Pharmacol. – 2015; 79 (6): 988–99.
  17. Wörz R. Long-term-treatment of chronic pain patients with flupirtine--on hepatotoxicity and persistent effectiveness from 7 months to 22 years // MMW Fortschr. Med. – 2014; 156 (Suppl. 4): 127–34.